Lu AG09222 for Migraine
(PROCEED Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It might be best to discuss this with the trial coordinators.
How does the drug Lu AG09222 differ from other migraine treatments?
Lu AG09222 is unique because it targets the GLU(K5) kainate receptor, which is involved in the pain pathways of migraines. This mechanism is different from traditional migraine treatments like triptans, which target serotonin receptors. By focusing on glutamate receptors, Lu AG09222 offers a novel approach to managing migraines.12345
Eligibility Criteria
This trial is for adults who have suffered from migraines for over a year, get them at least 4 days each month, and haven't found relief with 2-4 other preventive medications. They must have been diagnosed according to specific guidelines and had their first migraine before turning 51.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive injections of Lu AG09222 or placebo to determine the effective dose for migraine prevention
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Lu AG09222
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lundbeck A/S
Lead Sponsor
Charl van Zyl
H. Lundbeck A/S
Chief Executive Officer since 2023
Degree in Medical Biochemistry from the University of Cape Town, South Africa
Johan Luthman
H. Lundbeck A/S
Chief Medical Officer since 2019
MD from the University of Gothenburg, Sweden